CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

PharmaTimes
Original article

Oblenio doses first patients in phase 1a autoimmune trial

Phase 1LBL-051Positive
AI Analysis

Summary

Oblenio has dosed the first patients in a Phase 1a trial evaluating LBL-051, a tri-specific T cell engager for autoimmune indications.

Clinical Trial Data

Phase

1a

Importance:3/10
Sentiment:
0.50
Phase 1autoimmuneT cell engagertri-specificclinical trial
Related Companies

Read the original article

Published by PharmaTimes on August 5, 2026 10:33 AM

Read Original